Page last updated: 2024-09-04

sk&f 83959 and Parkinson Disease

sk&f 83959 has been researched along with Parkinson Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, J; Ma, L; Wang, F; Zhang, H; Zhen, X	1

Other Studies

1 other study(ies) available for sk&f 83959 and Parkinson Disease

Article	Year
Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. Neuropharmacology, 2007, Volume: 53, Issue:1 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Movement; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Serotonin Antagonists; Spiperone; Sympatholytics; Time Factors	2007

Article

Year

Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.

Neuropharmacology, 2007, Volume: 53, Issue:1

Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Movement; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Serotonin Antagonists; Spiperone; Sympatholytics; Time Factors

2007